Trial Profile
A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2022
Price :
$35
*
At a glance
- Drugs Moxidectin (Primary) ; Ivermectin
- Indications Onchocerciasis
- Focus Adverse reactions; Registrational
- Acronyms Ghana
- Sponsors Wyeth
- 13 Jun 2018 According to a United States (U.S.) Food and Drug Administration (FDA) media release, the agency has approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. The approval was based on data from this and a phase III trial (CT profile 700245034).
- 23 May 2014 New trial record